Author: Newsdesk

Posted on

DEADLINE ALERT for CACC, ACB, and PGEN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Nov. 16, 2020 (GLOBE NEWSWIRE) — The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected].

Credit Acceptance Corporation (NASDAQ: CACC)
Class Period: November 1, 2019 – August 28, 2020
Lead Plaintiff Deadline: December 1, 2020

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Credit Acceptance was topping off the pools of loans that they packaged and securitized with higher-risk loans; (2) that Credit Acceptance was making high interest subprime auto loans to borrowers that the Company knew borrowers would be unable to repay; (3) that the borrowers were subject to hidden finance charges, resulting in loans exceeding the usury rate ceiling mandated by state law; (4) that Credit Acceptance took excessive and illegal measures to collect debt from defaulted borrowers; (5) that, as a result, Credit Acceptance was likely to face regulatory scrutiny and possible penalties from various regulators or lawsuits; and (6) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Aurora Cannabis, Inc. (NYSE: ACB)
Class Period: February 13, 2020 – September 4, 2020
Lead Plaintiff Deadline: December 1, 2020


Shareholders with $50,000 losses or more are encouraged to contact the firm

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (2) the Company’s purported “business transformation plan” and cost reset failed to mitigate the foregoing issues; (3) accordingly, it was foreseeable that Aurora would record significant goodwill and asset impairment charges; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Precigen, Inc. f/k/a
Intrexon
Corporation (NASDAQ: PGEN, XON)
Class Period: May 10, 2017 – September 25, 2020
Lead Plaintiff Deadline: December 4, 2020

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company was using pure methane as feedstock for its announced yields for its methanotroph bioconversion platform instead of natural gas; (2) yields from natural gas as a feedstock were substantially lower than the aforementioned pure methane yields; (3) due to the substantial price difference between pure methane and natural gas, pure methane was not a commercially viable feedstock; (4) the Company’s financial statements for the quarter ended March 31, 2018 were false and could not be relied upon; (5) the Company had material weaknesses in its internal controls over financial reporting; (6) the Company was under investigation by the SEC since October 2018; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com.   If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com



Posted on

Voltron Therapeutics, Inc. to Participate in the 2020 Fall Defense TechConnect Virtual Innovation Summit

Company Selected as a 2020 TechConnect Defense Innovation Awardee

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) — Voltron Therapeutics, Inc. today announced that it will participate in the 2020 Fall TechConnect Virtual Innovation Conferences’ Virtual Defense TechConnect Innovation Summit. The conference will be held November 17-19, 2020.

Importantly, the Company was also selected as a 2020 TechConnect Defense Innovation Awardee.  The annual TechConnect Defense Innovation Awards recognizes the top 15% of submitted Challenge technologies as ranked by the Selection Committee.

Voltron’s COVID-19 vaccine, HaloVax, is being developed using the novel Self Assembling Vaccine technology exclusively licensed from the Massachusetts General Hospital’s Vaccine and Immunotherapy Center, provides a novel approach to attacking the virus, and an important alternative to first generation vaccines in development.

Entering its seventh year, the annual Defense TechConnect (DTC) Summit, co-located with the Fall SBIR/STTR Innovation Summit, brings together defense, private industry, federal agency, and academic leadership to accelerate state-of-the-art technology solutions for the warfighter and national security.

The DTC supports innovation imperatives in the new National Defense Strategy (NDS) and is a unique platform to reach thousands of public and private leaders focused on innovation and technology to support the warfighter. At last year’s Defense Innovation Summit, close to 1,000+ one-on-one meetings took place between small businesses and SBIR Federal Program Managers, 200+ booths and tabletop displays in the Exhibit Hall representing private sector companies and non-traditional innovators, and more than 30 breakout sessions focused on defense innovation areas of interest including but not limited to energy, cyber, biomedical, and command, control, communications, computers/intelligence, surveillance, and reconnaissance (C4ISR).

The DTC Summit is proud to once again host the Defense Innovation Technology Acceleration Challenges (DITAC), connecting emerging technologies with DOD component commands, officers, and acquisition experts. The annual DTC is one of the most well-attended defense innovation conferences of the year.

To learn more about the Virtual Defense TechConnect Summit and Expo, one of the most well-attended defense events of the year, please visit: https://events.techconnect.org/DTCFall/.

About Voltron Therapeutics, Inc.

Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital’s novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related Cancers). For more information, please visit www.voltrontx.com.

About HaloVax™, LLC

HaloVax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc. in joint venture with Hoth Therapeutics, Inc. (NASDAQ: HOTH) The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapy Center at the Massachusetts General Hospital. The vaccine is being designed from a validated platform to provide customized T cell immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus. For more information, please visit www.HaloVax.com. 

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.


Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCelerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Voltron’s current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Voltron’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, levels of activity, performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

Investor Contacts:

Matt Duffy
President
Voltron Therapeutics, Inc.
646-335-5923
[email protected]

Jason Assad
Investor Relations
Voltron Therapeutics, Inc.
678-570-6791
[email protected]



Posted on

SouthPoint Bancshares Announces Q3 2020 Earnings

SouthPoint Bancshares Announces Q3 2020 Earnings

BIRMINGHAM, Ala.–(BUSINESS WIRE)–
SouthPoint Bancshares, Inc. (SOUB), the parent company of SouthPoint Bank, announced a net income of $5,010,719, or $2.50 per share, for the third quarter year-to-date ended September 30, 2020, as compared to a net income of $3,665,103, or $1.83 per share, for the third quarter year-to-date ended September 30, 2019. Pre-tax and pre-provision income was $7,689,532 as of September 30, 2020 compared to $4,880,238 on September 30, 2019.

“We have finished another record-breaking quarter here at SouthPoint Bank,” said Steve Smith, Chairman, President and CEO. “Both our home mortgage division and commercial banking areas have had an excellent year. The mortgage division has greatly benefited from the reduction in long term fixed rates. Commercial loans are up 20 percent net of payoffs, which is a record growth percentage.”

Total assets in September 2020 grew to $557.1 million from $407.3 million in September 2019, while total loans grew to $434.2 million from $327.7 million in September 2019.

The home mortgage division grew net income 274 percent to $3,503,000 year-to-date in September 2020 from $937,000 year-to-date in September 2019.

“The sudden drop in short-term rates in the first quarter had a negative effect on our overall margins,” Smith said. “We have worked to counter this effect by realigning our balance sheet to reduce cost of funds and offset the reduction in floating rate loan yields.”

Despite the possibility of setbacks due to COVID, the bank continues to thrive and grow. The bank opened its fifth branch in Liberty Park, a subdivision in Vestavia Hills, AL.

“We are blessed to have a great team here who have weathered the uncontrollable COVID storm this year as essential workers. This team has helped our old and new customers through the Paycheck Protection Program with 650 unique business loans for a total of $72,000,000,” Smith said. “I am gratified by their work and dedication to this bank and this community and will always remember how they all pitched in to make positive impacts for all our stakeholders.”

The unaudited third quarter 2020 financials can be found on SouthPoint Bank’s website at www.southpoint.bank/investors.

About SouthPoint Bancshares, Inc:

SouthPoint Bancshares, Inc. is the parent company of SouthPoint Bank. SouthPoint was founded in 2005 in Birmingham, Alabama to create a local community bank dedicated to superior customer service for its customers. The bank has assets of approximately $535 million and has four bank branches in Birmingham, Gardendale, Trussville and Wilsonville with a fifth in progress in Liberty Park. The bank also operates a full-service mortgage division with six branches throughout the state of Alabama.

Forward-Looking Statements:

Certain statements in this release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which statements can generally be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “target,” “plan,” “project,” “continue,” or the negatives thereof, or other variations thereon or similar terminology, and are made on the basis of management’s plans and current analyses of the Company, its business and the industry as a whole. These forward-looking statements are subject to risks and uncertainties, including, but not limited to, economic conditions, competition, interest rate sensitivity and exposure to regulatory and legislative changes. The above factors, in some cases, have affected, and in the future could affect the Company’s financial performance and could cause actual results to differ materially from those expressed or implied in such forward-looking statements, even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.

For Media

Mackenzie Brown

AVP – Marketing

[email protected]

205-637-2309

For Investor Relations

Jeanne Noto

Investor Relations

[email protected]

205-503-5018

KEYWORDS: Alabama United States North America

INDUSTRY KEYWORDS: Banking Professional Services

MEDIA:

Posted on

Duke Energy joins utilities across the continent to protect customers from scams

– Utility Scam Awareness Day (Nov. 18) focuses on educating customers against fraud.

– As the pandemic continues, more scam attempts increasingly fail, but knowing what to look for is key.

– Simple tips can help guard your money, personal information.

PR Newswire

CHARLOTTE, N.C., Nov. 16, 2020 /PRNewswire/ — The phone rings. It’s Duke Energy. We’re on the way to disconnect your electric service unless you pay us over the phone right now. You follow the instructions and – just like that – you’ve been scammed.

Sadly, this is not an uncommon phone call. That’s why Duke Energy has again joined forces with utilities across the continent to bring awareness to these criminal scam tactics on the fifth annual Utility Scam Awareness Day on Nov. 18. Utility Scam Awareness Day is part of the week-long International Scam Awareness Week, an advocacy and awareness campaign focused on educating customers and exposing the tactics used by scammers.

“As the COVID-19 pandemic continues, it’s absolutely critical to remind all utility customers to beware of impostors attempting to scam them,” said Jared Lawrence, Duke Energy’s vice president of revenue services and metering. “We’ve made great progress as an industry in getting the word out the past few years, and the numbers continue to improve. But so do the scammers, and that’s why we must continue to keep our customers informed and aware so they don’t become the next victims. Together, we can stop scams.”

Recognized annually, Utility Scam Awareness Day was created by Utilities United Against Scams (UUAS), a consortium of nearly 150 U.S. and Canadian electric, water, and natural gas companies and their respective trade associations.

Scamming through the pandemic

Duke Energy – a founding member of UUAS – and the consortium’s other member companies have seen an increase in scam attempts appearing to take advantage of the uncertainty of the pandemic. In addition to the frequent impostor scam, some new tactics include bogus COVID-19 references to steal personal information. Although impostors continue to target utility customers, UUAS members and partners have succeeded in taking nearly 9,400 scam telephone numbers out of operation.

“At the height of the pandemic, scammers preyed on Duke Energy customers with an alarming frequency,” Lawrence said. “The good news? Most people didn’t fall for it.”

When the UUAS campaign started in 2016, more than 9 percent of Duke Energy customers who reported scams lost money, and so far this year less than 3 percent have reported falling for scams. That’s still nearly $400,000 of hard-earned money lost to scammers in less than a year, and the reason why more work needs to be done to get the word out.

“Customers need to be on high alert as we continue to see impostor utility scams rise across North America,” said UUAS Executive Director Monica Martinez. “Scammers demand money or personal information on the spot – usually with threatening language – and indicate that service will be disconnected immediately. Anyone and everyone, from senior households to small business owners, is at risk of being targeted.”

UUAS advises customers who suspect that they have been victims of fraud or who feel threatened during contact with a scammer to contact their local utility or law enforcement authorities. Here are tips to protect yourself from falling victim to utility scams:

Know what to look for

Common scam tactics include:    

  • Threat to disconnect: Scammers may aggressively tell a customer their utility bill is past due, and service will be disconnected—usually within an hour—if a payment is not made.
  • Request for immediate payment: Scammers might instruct a customer to purchase a prepaid card, cryptocurrency, or to send funds via a mobile app to make a bill payment.
  • Request for prepaid card or payment through certain mobile apps: Customers are instructed to pay with a prepaid debit card. The impostor asks for the prepaid card’s number, which grants instant access to the card’s funds. More recently, customers have also been instructed to send a payment through a mobile app. Duke Energy currently does not accept payments through the Cash App, Venmo or Zelle apps. However, customers can make payments on Duke Energy’s mobile app available in the Apple App Store for iOS and the Google Play Store for Android.
  • Personal information: During the COVID-19 crisis, criminals are promising to mail refund checks for overpayments on their accounts if they can confirm their personal data, including birthdays and, in some cases, Social Security numbers. Duke Energy will apply refunds as a credit to customers’ accounts and will not contact customers to verify personal information by phone, email or in person in order to mail a check.

Protect yourself

  • Customers should never purchase a prepaid card to avoid service interruption. Utility companies do not specify how customers should make a bill payment and always offer a variety of ways to pay a bill, including online payments, phone payments, automatic bank drafts, mail, or in person.
  • If someone threatens immediate service interruption, customers should be aware. Customers with past due accounts receive multiple advanced notices, typically by mail and in their regular monthly bill. Utilities will never notify of a disconnection in one hour or less.
  • If customers suspect someone is trying to scam them, they should hang up, delete the email, or shut the door. The utility should be contacted immediately at the number on the most recent monthly bill or on the utility’s official website, not the phone number the scammer provides. If customers ever feel that they are in physical danger, they should call 9-1-1.

Visit Duke Energy’s brand journalism site, illumination, to learn more about Lawrence’s involvement in founding Utilities United Against Scams and to download a call from a customer who reported being scammed.

Duke Energy
Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of the largest energy holding companies in the U.S. It employs 29,000 people and has an electric generating capacity of 51,000 megawatts through its regulated utilities and 2,300 megawatts through its nonregulated Duke Energy Renewables unit.

Duke Energy is transforming its customers’ experience, modernizing the energy grid, generating cleaner energy and expanding natural gas infrastructure to create a smarter energy future for the people and communities it serves. The Electric Utilities and Infrastructure unit’s regulated utilities serve 7.8 million retail electric customers in six states: North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky. The Gas Utilities and Infrastructure unit distributes natural gas to 1.6 million customers in five states: North Carolina, South Carolina, Tennessee, Ohio and Kentucky. The Duke Energy Renewables unit operates wind and solar generation facilities across the U.S., as well as energy storage and microgrid projects.

Duke Energy was named to Fortune’s 2020 “World’s Most Admired Companies” list and Forbes’ “America’s Best Employers” list. More information about the company is available at duke-energy.com. The Duke Energy News Center contains news releases, fact sheets, photos, videos and other materials. Duke Energy’s illumination features stories about people, innovations, community topics and environmental issues. Follow Duke Energy on Twitter, LinkedIn, Instagram and Facebook.

Media contact: 800.559.3853                                                    

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/duke-energy-joins-utilities-across-the-continent-to-protect-customers-from-scams-301173778.html

SOURCE Duke Energy

Posted on

GrowLife, Inc. Reports Increased Backlog and Highlights Positioning for Future Opportunity in Quarterly Filing

Company Files Quarterly Report on Financial and Operations Results from the Period Ending September 30, 2020

Summary:

  • GrowLife shipped $1.4M in revenue for the period
  • GrowLife reported a $1.9M sales order backlog, not included in revenue
  • GrowLife increased its blended gross margins to 38.1% for the nine months September 30, 2020, up from 32.5% during the three months ended September 30, 2019
  • GrowLife reduced operating expenses for the nine-month period ending September 30, 2020 by $2.8M when compared to the same period in 2019.
  • GrowLife focused on positioning its EZ-CLONE business, its base business, and its expanding genetics business to benefit from potential legislative change such as federal decriminalization of cannabis

KIRKLAND, Wash., Nov. 16, 2020 (GLOBE NEWSWIRE) — GrowLife, Inc. (OTC: PHOT) (“GrowLife” or the “Company”), one of the nation’s most recognized indoor cultivation product and service providers, today announced financial results for the period ending September 30, 2020 and provided further insight into the company’s positioning as a leader in propagation and genetics for the burgeoning cannabis and hemp industries.

The Company shipped $1.4M in revenue and ended with an additional $1.9M backlog of sales for the period ending September 30, 2020. Further, as a result of the cost reduction measures implemented in 2019, the company reported increased gross margins of 38.1% for the nine months September 30, 2020, up from 32.5% during the three months ended September 30, 2019 and a gross profit of $0.5M for the third quarter 2020. Finally, GrowLife reduced its operating expenses by $2.8M during the nine-month period ending September 30, 2020 and reduced cashed used in operations by $0.5M, from $2.0M to $1.5M.

“While 2020 has not been without its challenges, I am proud to report that GrowLife continues to generate new sales, especially in our EZ-CLONE business, and further position ourselves to capitalize on the expanding opportunities in legalized hemp as well as the impending legalization of cannabis,” said GrowLife CEO Marco Hegyi. “We recognize that shipping the $1.9M backlog of sales yet unshipped products could have brought us extremely close to profitability. Therefore, we are seeking to scale up production to meet demand by the majority owned EZ CLONE subsidiary. I believe we are taking all the necessary steps to realize this potential for our shareholders as soon as possible.”

About GrowLife, Inc.

GrowLife, Inc. (PHOT) aims to become the nation’s largest cultivation service provider for cultivating organics, herbs and greens and plant-based medicines. Our mission is to help make our customers successful. Through a network of local representatives covering the United States and Canada, regional centers and its e-Commerce team, GrowLife provides essential goods and services including media, industry-leading hydroponics and soil, plant nutrients, and thousands of more products to specialty grow operations. GrowLife is headquartered in Kirkland, Washington and was founded in 2012.

Investor Relations Contact:

[email protected]
206-483-0059

FORWARD LOOKING STATEMENT:

This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of GrowLife, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words may, would, will, expect, estimate, can, believe, potential and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond GrowLife, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors.



Posted on

Aegis Sciences Corporation Launches Combined Test for SARS-CoV-2 and Influenza A/B Virus

NASHVILLE, Tenn., Nov. 16, 2020 (GLOBE NEWSWIRE) — Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and consulting services to providers, has launched a combined test for SARS-CoV-2 and influenza A/B virus for individuals suspected of respiratory viral infection consistent with COVID-19.

Reducing the spread of respiratory illnesses, like flu, this fall and winter is more important than ever due to the COVID-19 pandemic. Since symptoms of respiratory viral infection due to SARS-CoV-2 and influenza can be similar, a multiplex assay serves as a single test to diagnose infection caused by one of three viruses. Testing for all three viruses at the same time will allow for more efficient testing and diagnosis to help reduce the spread of these viruses in the community and improve patient care.

The combination COVID-19 + FLU A/B test is a reverse transcriptase polymerase chain reaction (RT-PCR) molecular test intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A virus, and/or influenza B virus. Respiratory specimens are collected via nasopharyngeal, oropharyngeal, nasal mid-turbinate or anterior nares from individuals suspected of respiratory viral infection consistent with COVID-19.

“Our validated testing method for SARS-CoV-2 and influenza A/B has the sensitivity to distinguish between these respiratory viruses and the specificity to detect the most common influenza virus subtypes causing illness during the flu season with no observed cross-reactivity with other human respiratory viruses, bacteria, and yeast,” said Dr. Cyndi Clark, Aegis’s Biopharma Laboratory Manager.

“With the flu season looming and COVID-19 surging, laboratory testing that can distinguish between SARS-CoV-2 and influenza virus infections and identify coinfection will be critical to patient care and public health response,” said Dr. Frank Basile, CEO of Aegis Sciences Corporation. “From the beginning, we have been committed to a 24-hour turnaround time for test results. Producing test results that are fast and accurate is even more critical as we enter this season.”

Aegis has the capacity to perform 60,000 tests per day within a targeted 24-hour turnaround time. Aegis will report testing results to State Departments of Health and to the CDC in accordance with applicable public health emergency response requirements. Aegis is accredited for all testing it performs under its College of American Pathologists (CAP) accreditation #8853197. 

About Aegis Sciences Corporation

Founded in 1990, Aegis Sciences Corporation is a laboratory sciences company based in Nashville, Tenn., that provides science-driven testing and consulting services for clients such as healthcare providers, pharmaceutical companies, professional and amateur sports organizations, leading college and university athletic programs, Fortune 500 corporations, and government agencies throughout the United States. For more information, please visit http://www.aegislabs.com/.

Minh Le
615-327-7999
[email protected]



Posted on

TAB Bank Provides Additional $4 Million Credit Facility to Support Related Canadian Entity of an Existing Client

OGDEN, Utah, Nov. 16, 2020 (GLOBE NEWSWIRE) — TAB Bank is pleased to announce it has provided an additional $4 million revolving credit facility to support related Canadian entity of an existing client.   This entity of TAB’s existing client is a key provider of aftermarket support solutions for the global aerospace and defense industries including the maintenance, repair, and overhaul of engines, components, and related accessories.

The relationship was first formed in May of 2018 to refinance and restructure the debt of the US parent and its three domestic operating entities and to provide additional liquidity for growth. The new facility for the Canadian arm of this US client will be used to refinance previous senior debt facilities in Canada and provide capital for ongoing working capital requirements. By having all facilities with one institution it will streamline the internal management of funds and improve efficiencies in the day to day operations.

TAB Bank looks forward to continuing this successful relationship and partnering with the management teams both in the US and Canada as they continue to expand and evolve the company’s services.

TAB Bank provides custom working capital solutions to commercial businesses across a wide range of industries. These solutions can be customized to meet the needs of companies in all stages of the business life cycle and during any economic conditions. TAB Bank does this through a variety of asset-based structures including Asset-Based Revolving Loans, Accounts Receivable Financing, Lines of Credit, and Equipment Finance. TAB’s lending options can also be combined with a full suite of business banking solutions and Treasury Management Services.

Brett Horwitz is TAB Bank’s Managing Director and Head of Operations for the Western Region based in Southern California. Brett has years of experience developing client relationships and structuring credit facilities in the asset-based lending arena. Brett can be reached at 949.466.5255 or at [email protected].

Contact Information:

Trevor Morris
Director of Marketing
801-624-5172
[email protected]
Twitter – @TABBank
Facebook – facebook.com/TABbank



Posted on

VEON Co-CEO Kaan Terzioğlu Elected to Serve on GSMA Board of Directors

PR Newswire

AMSTERDAM, Nov. 16, 2020 /PRNewswire/ – VEON Ltd. (NASDAQ: VEON) (Euronext Amsterdam: VEON), a leading global provider of connectivity and internet services, announces that Kaan Terzioğlu has been elected to the Board of Directors of the GSMA, the mobile industry’s leading global organization that brings together more than 750 operators and nearly 400 ecosystem companies.

Kaan Terzioğlu’s appointment was confirmed amongst those of 26 industry leaders elected to the GSMA’s Board for a two-year term, each of whom will serve the mobile industry’s leading global body from January 2021 to December 2022.

Commenting on the announcement, Kaan Terzioğlu, co-CEO of VEON Group, said:

“The role of mobile communications has never been more essential to the lives and livelihoods of our customers, and to the current and future prosperity of the economies we connect. I am delighted to have the opportunity to join the GSMA Board and serve the industry as we navigate this unprecedented period, and look forward to bringing insights from across the wide and diverse operational footprint of the VEON Group of companies.”

The VEON Group operates in 9 countries across the globe, which together account for 10% of the world’s population. Its operating companies Beeline, Kyivstar, Jazz, Djezzy and Banglalink deliver mobile and fixed line services to more than 200 million subscribers, helping to bridge the digital divide throughout the nations they serve, particularly through 4G connectivity. VEON’s operating companies also provide a growing range of new digital services that are transforming the experience of customers through mobile-led content, financial services and a host of B2B offerings.

About VEON

VEON is a NASDAQ and Euronext Amsterdam-listed global provider of connectivity and internet services, headquartered in Amsterdam. Our vision is to empower customer ambitions through technology, acting as a digital concierge to guide their choices and connect them with resources that match their needs. 

For more information visit: http://www.veon.com.

VEON Contacts

Investor Relations & Communications

Nik Kershaw

[email protected]                         
Tel: +31-20-79-77-200

 

Cision View original content:http://www.prnewswire.com/news-releases/veon-co-ceo-kaan-terziolu-elected-to-serve-on-gsma-board-of-directors-301173772.html

SOURCE VEON Ltd

Posted on

DEADLINE ALERT for FLDM, GOCO, and NXTC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Nov. 16, 2020 (GLOBE NEWSWIRE) — The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected].

Fluidigm Corporation (NASDAQ: FLDM)
Class Period:  February 7, 2019 – November 5, 2019
Lead Plaintiff Deadline:  November 20, 2020

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Fluidigm was experiencing longer sales cycles; (2) that, as a result, Fluidigm’s revenue was reasonably likely to decline; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

GoHealth, Inc. (NASDAQ: GOCO)
Class Period:  July, 2020 IPO
Lead Plaintiff Deadline:  November 20, 2020

The complaint alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that at the time of the IPO: (1) the Medicare insurance industry was undergoing a period of elevated churn, which had begun in the first half of 2020; (2) GoHealth suffered from a higher risk of customer churn due to its unique business model and limited carrier base; (3) GoHealth suffered from degradations in customer persistency and retention as a result of elevated industry churn, vulnerabilities that arose from the Company’s concentrated carrier business model, and its efforts to expand into new geographies, develop new carrier partnerships and worsening product mix; (4) GoHealth had entered into materially less favorable revenue sharing arrangements with its external sales agents; and (5) these adverse financial and operational trends were internally projected by GoHealth to continue and worsen following the IPO.

NextCure, Inc. (NASDAQ: NXTC)
Class Period:   November 5, 2019 – July 14, 2020
Lead Plaintiff Deadline:  November 20, 2020


Shareholders with $100,000 losses or more are encouraged to contact the firm

The complaint filed alleges that Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) NextCure possessed NC318 data that showed a lack of efficacy and objective responses; (2) as a result, NC318 was not, in fact, effective in treating most tumor types; (3) as a result, the NC318 application was proving to be limited (if even useful at all); (4) as a result of the foregoing, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.  If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com.  If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com



Posted on

IMMINENT SHAREHOLDER DEADLINE: BioMarin Pharmaceutical, Inc. Sued for Violations of the Federal Securities Laws; Investors Who Lost Money Should Contact Block & Leviton LLP Before November 24, 2020

BOSTON, Nov. 16, 2020 (GLOBE NEWSWIRE) — On August 19, 2020, BioMarin Pharmaceutical, Inc. (NASDAQ: BMRN) stunned the markets when it announced that the U.S. Food and Drug Administration had issued a Complete Response Letter (CRL) to the Company’s Biologics License Application (BLA) for valoctocogene roxaparvovec (VR) gene therapy for severe hemophilia A. In the CRL, the FDA informed BioMarin that the Company’s BLA was not ready for approval. On this news, BioMarin’s stock fell $41.82 per share, or over 35%, in just one day.

In the CRL, the FDA concluded that “the differences between” BioMarin’s Phase 1/2 study and the Phase 3 study for VR “limited [the FDA’s] ability to rely on the Phase 1/2 study to support durability of effect.” The FDA therefore recommended that BioMarin complete its Phase 3 study (not due to conclude until November 2021) and that BioMarin submit two-year follow-up safety and efficacy data on all study participants.

A lawsuit alleging violations of federal securities laws has been filed against BioMarin and certain of its officers and directors. The suit alleges that beginning on February 28, 2020, BioMarin misled investors about its BLA, namely, that the Company misrepresented the differences between its Phase 1/2 and Phase 3 studies for VR, which limited the reliability of the Phase 1/2 study to support FDA approval. According to the lawsuit, the August 19, 2020 disclosure of the CRL from the FDA shocked the market because of the Company’s previous statements about the BLA and the reliability of the Phase 1/2 study.

The lawsuit was filed in the U.S. District Court for the Northern District of California, and is captioned Tsantes v. BioMarin Pharmaceutical, Inc., et al., No. 20-cv-06719.

If you purchased or acquired shares of BioMarin between February 28, 2020 and August 18, 2020 and have questions about your legal rights or possess information relevant to this matter, please contact Block & Leviton attorneys at (617) 398-5600, via email at [email protected], or at https://www.blockleviton.com/cases/bmrn. The deadline to move the Court to be appointed lead plaintiff is November 24, 2020.

Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country’s financial markets. The firm represents many of the nation’s largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm’s lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: [email protected]
SOURCE: Block & Leviton LLP
www.blockleviton.com